MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$16,358K
Free Cash flow
-$28,257K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from issuance of common...
Accounts payable
Accrued expenses and other liabi...
Others
Negative Cash Flow Breakdown
Deposit and other long-term asse...
Purchases of property and equipm...
Net accretion of discount on mar...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2025-09-30
2025-06-30
Net loss
-47,652
-96,210
Depreciation and amortization
465
1,218
Stock-based compensation expense
2,349
5,201
Net accretion of discount on marketable securities
16
528
Non-cash lease expense
83
82
Non-cash sublease loss
0
982
Loss on disposal of property and equipment
-8
-
Other
-1
-12
Prepaid expenses and other current assets
-1,135
-1,568
Deposit and other long-term assets
551
125
Accounts payable
7,739
3,103
Accrued expenses and other liabilities
7,190
3,625
Lease liability
1,134
-466
Net cash used in operating activities
-28,115
-81,538
Purchases of marketable securities
0
1,976
Maturities of marketable securities
2,000
65,500
Purchases of property and equipment
142
340
Net cash provided by (used in) investing activities
1,858
63,184
Proceeds from issuance of common stock and pre-funded warrants in private placements, net of issuance costs
9,899
0
Proceeds from issuance of common stock pursuant to option exercises
0
0
Proceeds from employee stock purchase plan
0
120
Net cash provided by financing activities
9,899
120
Net (decrease) increase in cash and cash equivalents and restricted cash
-16,358
-18,234
Cash and cash equivalents at beginning of period
62,628
-
Cash and cash equivalents at end of period
28,036
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock and...
$9,899K
Maturities of marketable
securities
$2,000K
Net cash provided by
financing activities
$9,899K
Net cash provided by
(used in) investing...
$1,858K
Canceled cashflow
$142K
Net (decrease)
increase in cash and cash...
-$16,358K
Canceled cashflow
$11,757K
Accounts payable
$7,739K
Accrued expenses and
other liabilities
$7,190K
Stock-based compensation
expense
$2,349K
Prepaid expenses and
other current assets
-$1,135K
Lease liability
$1,134K
Depreciation and
amortization
$465K
Non-cash lease expense
$83K
Loss on disposal of
property and equipment
-$8K
Other
-$1K
Purchases of property and
equipment
$142K
Net cash used in
operating activities
-$28,115K
Canceled cashflow
$20,104K
Net loss
-$47,652K
Deposit and other
long-term assets
$551K
Net accretion of
discount on marketable...
$16K
Buy us a coffee
Adverum Biotechnologies, Inc. (ADVM)
Adverum Biotechnologies, Inc. (ADVM)